Biomerieux AAQS 2024

Biomerieux làm gì?

Biomerieux SA is a French company that operates in the field of in vitro diagnostics. The company was founded in 1963 by French biologist Alain Merieux and has since continued to grow. Today, Biomerieux employs around 12,000 people in over 150 countries worldwide and is listed on the Paris Stock Exchange. Biomerieux's business model is based on the development, production, and marketing of diagnostic products for various areas of medicine. This includes infectious diseases, cancer, and cardiovascular diseases. The company is divided into two main business segments: Clinical Diagnostics and Industrial Microbiology. Under the Clinical Diagnostics segment, Biomerieux offers a wide range of diagnostic products for infectious diseases, including molecular diagnostics, blood-based tests, and laboratory automation solutions. Some of the most well-known products include the VIDAS immunodiagnostic test, the FilmArray multiplex PCR test, and the VITEK automated system for microorganism identification. Under the Industrial Microbiology segment, Biomerieux is a leading provider of products for the microbiological analysis of food, beverages, and pharmaceutical products. The company offers a wide range of products for microbiological quality control, which help ensure the safety and quality of food and pharmaceutical products. These include the TEMPO system for assessing microorganism growth and the Bactalert blood culture system for rapid detection of bacteria in blood cultures. In addition to its main business segments, Biomerieux also offers specialty products for use in veterinary diagnostics and water analysis. The company works closely with clinical laboratories and health authorities to improve the diagnosis of infectious diseases and combat epidemics. Over the years, Biomerieux has built a strong research and development department focused on developing innovative diagnostic products. The company has also made a number of strategic acquisitions to expand its product portfolio and enter new markets. For example, in 2020, Biomerieux acquired Suzhou Hybiome Biomedical Engineering in China to strengthen its presence in the Chinese market. In summary, Biomerieux is a leading company in the field of in vitro diagnostics. Its wide range of products and global network make it an important partner for laboratories, hospitals, and the food and pharmaceutical industries. With its strong research and development department and strategic acquisitions, Biomerieux will continue to play a crucial role in the fight against infectious diseases and the improvement of patient care. Biomerieux ist eines der beliebtesten Unternehmen auf Eulerpool.com.